Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Evoke Pharma stock opened at $2.50 on Monday. Evoke Pharma has a 52-week low of $1.94 and a 52-week high of $12.32. The stock has a fifty day moving average price of $3.32 and a two-hundred day moving average price of $4.31. The firm has a market capitalization of $3.73 million, a P/E ratio of -0.23 and a beta of 0.30.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The firm had revenue of $3.31 million for the quarter, compared to analyst estimates of $3.08 million. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC grew its holdings in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after buying an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 at the end of the most recent reporting period.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.